FDA Denied Teva 180-Day Exclusivity on Generic Actonel After Review Delay

Drug Industry Daily
The FDA denied Teva its 180-day exclusivity period for a version of Warner Chilcott’s osteoporosis drug Actonel 150 mg because the agency itself didn’t tentatively approve Teva’s ANDA fast enough, according to an internal agency document.

To View This Article:


Subscribe To Drug Industry Daily